NACE 21.20 in FR. Official registry identity, source coverage and the current valuation evidence status on one public company profile.
The latest filing has no usable positive EBITDA or the sector multiple is not available yet.
Create a free account to add verified turnover, normalised EBITDA, debt and one-offs for ETHYPHARM in a private workspace.
We keep this public page conservative, so weak filings never become a false price.The page can still show filed facts, but the automatic public range is blocked when those facts would make the multiple misleading.
ETHYPHARM is a business in NACE sector 21.20 based in France. The company was founded in 1978, incorporated as a 5710.
ETHYPHARM is listed in French National Business Register (RNE/INPI) under registry number 311999833. The public employee band is 41, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 21.20 cluster, public-record data is filed annually via the national company registry.
Across the 2017-2024 window revenue has stayed broadly flat, moving from €129,399,723 to €134,730,737.
The most recent annual filing covers 2024 (period end 2024-12-31).
If you are researching ETHYPHARM for acquisition, investment, or due-diligence purposes, this page consolidates firmographics, filed accounts and the reason a public valuation curve is not shown yet.
ETHYPHARM's public data is not clean enough for an automated valuation curve yet. Owner or advisor data can add the missing turnover, normalised EBITDA and adjustments.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202431 Dec 2024 | €134,730,737 | - | €221,594,258 | €102,453,588 | - |
| 202331 Dec 2023 | €132,673,516 | - | €183,132,625 | €107,962,435 | - |
| 202231 Dec 2022 | €117,140,213 | - | €178,055,096 | €101,876,498 | - |
| 202131 Dec 2021 | €120,390,365 | - | €174,835,410 | €99,443,189 | - |
| 202031 Dec 2020 | €133,610,652 | - | €238,647,469 | €145,082,361 | - |
| 201931 Dec 2019 | €128,526,883 | - | €242,673,699 | €139,726,169 | - |
| 201831 Dec 2018 | €134,941,498 | - | €269,754,172 | €167,695,553 | - |
| 201731 Dec 2017 | €129,399,723 | - | €266,622,179 | €159,011,953 | - |
ETHYPHARM was founded in 1978 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
ETHYPHARM is registered under NACE 21.20: NACE 21.20. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via French National Business Register (RNE/INPI).
This page shows public filed company data and valuation-readiness context for ETHYPHARM; it does not show an automated public valuation range. The filed figures may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
